I received an e-mail this morning from Leslie who was the producer and director of the short video I filmed about the Provenge issue at the FDA. (you can view the video at: Joel's Provenge Video Leslie asked that I sign a petition asking for a formal inquiry into the conflict of interest (COI) issues [...]
The FDA has approved the first generic versions of Fosamax (alendronate sodium tablets), used to treat osteoporosis. Osteoporos is a condition that causes thinning and weakening of bones and is often one of the many significant side effects from Hormone Therapy. Teva Pharmaceuticals USA has received approval to manufacture alendronate sodium tablets in three once-daily [...]
If you have not yet read yesterday's post please do so before reading this post. Among the most valuable communication tools created as a result of the National Cancer Act of 1971 is the NCI's annual report on The Nation's Investment in Cancer Research, which was released this week. Often referred to as the "bypass [...]
Have you ever danced with the Dev by the pale moonlight? Well, I have and it's silly, unexpected fun (you should not have because he's my son). About a month ago we started to have our stress-relieving dance parties. We always have one on the weekend, although during the week the urge to party can [...]
At the National Cancer Advisory Board's (NCAB) February 5 meeting, NCI Director Dr. John Niederhuber briefed committee members on the Institute's operating budget for fiscal year (FY) 2008. The $4.8 billion appropriation is essentially flat compared with FY 2007. Because of the rate of inflation, this will require NCI leaders to initiate 3-percent reductions across [...]